Search Results - "Jansen, Marleen"

Refine Results
  1. 1
  2. 2
  3. 3

    Neonatal and carrier screening for rare diseases: how innovation challenges screening criteria worldwide by Cornel, Martina C., Rigter, Tessel, Jansen, Marleen E., Henneman, Lidewij

    Published in Journal of community genetics (01-04-2021)
    “…Screening for rare diseases first began more than 50 years ago with neonatal bloodspot screening (NBS) for phenylketonuria, and carrier screening for Tay-Sachs…”
    Get full text
    Journal Article
  4. 4

    Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective by Rigter, Tessel, Jansen, Marleen E, de Groot, Jordy M, Janssen, Susan W J, Rodenburg, Wendy, Cornel, Martina C

    Published in Frontiers in genetics (31-01-2020)
    “…Aberrant pharmacogenetic variants occur in a high proportion of people and might be relevant for the prescription of over 26 drugs in primary care. Early…”
    Get full text
    Journal Article
  5. 5

    International differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents by Jansen, Marleen E, Metternick-Jones, Selina C, Lister, Karla J

    Published in European journal of human genetics : EJHG (01-01-2016)
    “…Despite international adoption of newborn bloodspot screening (DBS), no two countries' screening programs are the same. This article aims to understand what…”
    Get full text
    Journal Article
  6. 6

    Pursuing Public Health Benefit Within National Genomic Initiatives: Learning From Different Policies by Onstwedder, Suzanne M, Jansen, Marleen E, Leonardo Alves, Teresa, Cornel, Martina C, Rigter, Tessel

    Published in Frontiers in genetics (24-05-2022)
    “…Population-based genomic research is expected to deliver substantial public health benefits. National genomics initiatives are widespread, with large-scale…”
    Get full text
    Journal Article
  7. 7

    Measuring Agility in Tennis, Badminton, and Squash: A Systematic Review by Jansen, Marleen G. T., Huijgen, Barbara C. H., Faber, Irene R., Elferink-Gemser, Marije T.

    Published in Strength and conditioning journal (01-12-2021)
    “…A systematic review in PubMed, Web of Science, SPORTDiscus, PsycINFO, and Google Scholar was conducted to provide a state-of-the-science overview of agility…”
    Get full text
    Journal Article
  8. 8

    Comment on Jones et al. Application of a Novel Algorithm for Expanding Newborn Screening for Inherited Metabolic Disorders across Europe. Int. J. Neonatal Screen. 2022, 8 , 20 by Maase, Rose, Jansen, Marleen E, Heijnen, Marie-Louise, Dekkers, Eugenie

    “…With innovations in both the screening methodologies and treatment of diseases, newborn screening (NBS) programmes are confronted with an increasing number of…”
    Get full text
    Journal Article
  9. 9

    Design of a Tennis-Specific Agility Test (TAT) for Monitoring Tennis Players by Jansen, Marleen G.T., Elferink-Gemser, Marije T., Hoekstra, Aldo E., Faber, Irene R., Huijgen, Barbara C. H.

    Published in Journal of human kinetics (31-10-2021)
    “…Agility is an important ability for tennis players. To be successful in the rallies, players must perform rapid, multidirectional movements in response to the…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    Expanded Neonatal Bloodspot Screening Programmes: An Evaluation Framework to Discuss New Conditions With Stakeholders by Jansen, Marleen E, Klein, Anne W, Buitenhuis, Erika C, Rodenburg, Wendy, Cornel, Martina C

    Published in Frontiers in pediatrics (22-02-2021)
    “…Neonatal bloodspot screening (NBS) programmes that screen for rare but serious conditions are expanding worldwide. Fast developments for testing and treatment…”
    Get full text
    Journal Article
  13. 13

    Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users by Jansen, Marleen E, Rigter, Tessel, Fleur, Thom M C, Souverein, Patrick C, Verschuren, W M Monique, Vijverberg, Susanne J, Swen, Jesse J, Rodenburg, Wendy, Cornel, Martina C

    Published in Genes (10-02-2023)
    “…Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients…”
    Get full text
    Journal Article
  14. 14

    Policy Guidance for Direct-to-Consumer Genetic Testing Services: Framework Development Study by Onstwedder, Suzanne Maria, Jansen, Marleen Elizabeth, Cornel, Martina Cornelia, Rigter, Tessel

    Published in Journal of medical Internet research (17-07-2024)
    “…The online offer of commercial genetic tests, also called direct-to-consumer genetic tests (DTC-GTs), enables citizens to gain insight into their health and…”
    Get full text
    Journal Article
  15. 15

    Potential protective effect of a G>A SNP in the 3'UTR of HLA-A for Chlamydia trachomatis symptomatology and severity of infection by Jansen, Marleen E, Branković, Ivan, Spaargaren, Joke, Ouburg, Sander, Morré, Servaas A

    Published in Pathogens and disease (01-03-2016)
    “…The interindividual differences in response to Chlamydia trachomatis (CT) infections are for an important part based on the differences in our host genetic…”
    Get full text
    Journal Article
  16. 16

    Parental perspectives on retention and secondary use of neonatal dried bloodspots: a Dutch mixed methods study by Jansen, Marleen E, van den Bosch, Lion J M, Hendriks, Marjolein J, Scheffer, Mariska M J, Heijnen, Marie-Louise, Douglas, Conor M W, van El, Carla G

    Published in BMC pediatrics (09-07-2019)
    “…Neonatal bloodspot screening (NBS) identifies conditions to offer early intervention and minimize irreversible damage. NBS policies guide a comprehensive…”
    Get full text
    Journal Article
  17. 17

    Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity by Jansen, Marleen E, Rigter, T, Rodenburg, W, Fleur, T M C, Houwink, E J F, Weda, M, Cornel, Martina C

    Published in Frontiers in pharmacology (23-08-2017)
    “…Advances from pharmacogenetics (PGx) have not been implemented into health care to the expected extent. One gap that will be addressed in this study is a lack…”
    Get full text
    Journal Article
  18. 18

    Expanding Neonatal Bloodspot Screening: A Multi-Stakeholder Perspective by van Dijk, Tessa, Kater, Adriana, Jansen, Marleen, Dondorp, Wybo J., Blom, Maartje, Kemp, Stephan, Langeveld, Mirjam, Cornel, Martina C., van der Pal, Sylvia M., Henneman, Lidewij

    Published in Frontiers in pediatrics (06-10-2021)
    “…Neonatal bloodspot screening (NBS) aims to detect treatable disorders in newborns. The number of conditions included in the screening is expanding through…”
    Get full text
    Journal Article
  19. 19

    Informing Parents about Newborn Screening: A European Comparison Study by IJzebrink, Amber, van Dijk, Tessa, Franková, Věra, Loeber, Gerard, Kožich, Viktor, Henneman, Lidewij, Jansen, Marleen

    “…Knowledge about newborn screening (NBS) is an important factor for parents to make an informed decision about participation. In Europe, countries inform…”
    Get full text
    Journal Article
  20. 20

    Policy Making in Newborn Screening Needs a Structured and Transparent Approach by Jansen, Marleen E, Lister, Karla J, van Kranen, Henk J, Cornel, Martina C

    Published in Frontiers in public health (21-03-2017)
    “…Newborn bloodspot screening (NBS) programs have expanded significantly in the past years and are expected to expand further with the emergence of genetic…”
    Get full text
    Journal Article